Phase 1 Eczema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Part 1 only: You are between 18 and 55 years old at the time of signing the consent form
- Part 2 only: You are between 18 and 70 years old at the time of your screening appointment
- Part 1 only: You are in generally good health, confirmed by a full medical check-up including blood tests, heart tracing (ECG), and physical examination
- Your body weight is over 50 kg (110 lbs) and your body mass index (BMI) falls between 17.5 and 40
- Part 2 only: You have been diagnosed with chronic atopic dermatitis (also called eczema) for at least 1 year before the study starts
- Part 2 only: Standard skin treatments (not including medications that suppress the immune system) have not worked well enough for at least 4 consecutive weeks within a recent period, or a doctor has documented a medical reason why skin-applied treatments are not appropriate for you
- Part 2 only: Your eczema is classed as moderate to severe, confirmed by specific skin scoring measurements at both your screening and baseline appointments (confirm with trial site)
- Part 2 only: Apart from eczema symptoms, you are otherwise in generally good health based on a full medical check-up
- Part 2 only: If you have other health conditions that are well controlled and do not require any medications that are not allowed in this trial, you may still be eligible — for example, mild or moderate asthma that is well managed with low-level treatment
Who may not be able to join:
- You have a history of a serious systemic infection that required a hospital stay and intravenous antibiotics or similar treatments
- You have ever been diagnosed with a lymph node or blood cell disorder, or any type of cancer
- You have a significant history of serious illness affecting the blood, kidneys, hormones, lungs, digestive system, heart, liver, mental health, nervous system, or immune system
- You have had major surgery or a serious injury within 1 month before the first dose of the study treatment
- You have active, hidden, or previously untreated tuberculosis (TB), confirmed by a specific blood test and medical history (confirm with trial site)
- Part 2 only: You currently have another active inflammatory skin condition other than eczema
- Part 2 only: You have a skin condition or active skin infection that could interfere with assessing your eczema or your response to treatment — including certain infections treated in the week or two before the study starts
- Part 2 only: Your skin type scores 5 or higher on the Fitzpatrick Skin Type scale, which is a measure of skin tone and how it reacts to sun (confirm with trial site)
- Part 2 only: You have a history of severe allergic reactions (anaphylaxis), unless your reaction was to a single, known, and avoidable substance (such as aspirin or penicillin), you carry appropriate emergency treatment, and you know how to manage such a reaction
- Part 2 only: You have taken part in another experimental treatment trial for eczema, psoriasis, rheumatoid arthritis, or similar inflammatory conditions in the past year — this needs to be discussed with the trial team
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Phone: 1-800-718-1021
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and serious adverse events (SAEs) Following single ascending doses (SAD); Number of Participants with Clinically significant Laboratory Abnormalities Following SAD; Number of Participants with Change from Baseline in Electrocardiogram (ECG) Findings Following SAD; Number of Participants with Clinically Significant Change from Baseline in Vital Signs Following SAD; Number of Participants with Clinically Significant Change from Baseline in Cardiac Telemetry Findings Following SAD; Number of Participants With Tr...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.